AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
AbbVie (NYSE: ABBV) has scheduled its first-quarter 2025 financial results announcement for Friday, April 25, 2025, before market opening. The company will host a live webcast earnings conference call at 8 a.m. Central time, which will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived version of the session will be made available later the same day.
AbbVie (NYSE: ABBV) announced new data presentations at the upcoming AACR Annual Meeting (April 25-30, 2025), highlighting advances in early oncology research. The company will showcase two key investigational molecules:
1. ABBV-969: A novel dual-targeted antibody-drug conjugate (ADC) targeting STEAP1/PSMA in Phase 1 trials for metastatic castration-resistant prostate cancer. The drug uses a proprietary cytotoxic topoisomerase 1 inhibitor payload.
2. ABBV-514: A novel CCR8-targeting antibody in Phase 1 trials for non-small cell lung cancer, head and neck cancer, and other solid tumors. Preclinical data shows strong monotherapy activity, including in anti-PD-1 resistant models.
Additional presentations will focus on real-world-data analyses regarding treatment resistance and biomarker identification, including studies on folate receptor alpha expression in ovarian cancers and immunotherapy response in non-small cell lung cancer.
Allergan Aesthetics, an AbbVie company, will showcase its innovation and expertise at the Anti-Aging and Aesthetics Medicine World Congress (AMWC) in Monaco from March 27-29, 2025. The event will highlight the new AA Signature program, an innovative treatment planning approach, and celebrate 10 years of MD Codes™.
The congress features four expert-led educational events through the Allergan Medical Institute (AMI), including two major symposia: 'Design your patients' look with the NEW Signature approach' and a special session celebrating MD Codes™' decade of excellence. The program includes live injection sessions and a fireside chat with Dr. Maurício de Maio.
Additional highlights include the Science of Aging™ Symposium focusing on scientific advances in aging, and a Global Aesthetics Medical Affairs Symposium exploring the impact of aesthetic medicine on emotional well-being. The event will also feature eleven E-Poster presentations and Meet the Expert sessions at the Allergan Aesthetics booth.
AbbVie (ABBV) announced final analysis results from the Phase 3 MIRASOL trial for ELAHERE® in treating folate receptor alpha-positive platinum-resistant ovarian cancer. After 30.5 months median follow-up, the drug showed:
- 32% reduction in death risk compared to chemotherapy
- Median progression-free survival of 5.59 months vs 3.98 months for chemotherapy
- 41.9% objective response rate vs 15.9% for chemotherapy
- Median overall survival of 16.85 months vs 13.34 months for chemotherapy
The study included 453 patients with high-grade serous epithelial PROC. Common side effects included blurred vision, keratopathy, and abdominal pain, with lower rates of serious adverse events compared to chemotherapy. ELAHERE received full FDA approval in March 2024 and European Commission approval in November 2024.
AbbVie (NYSE: ABBV) has announced its upcoming participation in the Leerink Partners Global Healthcare Conference scheduled for Tuesday, March 11, 2025. The company's management team will engage in a fireside chat presentation starting at 7:40 a.m. Central time.
Investors and interested parties can access a live audio webcast of the presentation through AbbVie's Investor Relations website at investors.abbvie.com. For those unable to attend the live session, an archived version will be made available on the same day.
AbbVie (NYSE: ABBV) and Gubra A/S have announced a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for obesity treatment. This partnership marks AbbVie's strategic entry into the obesity market.
The agreement includes a $350 million upfront payment to Gubra, with potential additional payments of up to $1.875 billion in development, commercial, and sales milestones, plus tiered royalties on global net sales. AbbVie will lead global development and commercialization activities.
GUB014295, currently in Phase 1 clinical trials, is an agonist that activates amylin and calcitonin receptors. The compound works by triggering appetite suppression signals to the brain, reducing food intake, and delaying gastric emptying. This development addresses a significant global health concern, with approximately 900 million adults affected by obesity.
AbbVie (NYSE: ABBV) received a positive CHMP opinion recommending approval of upadacitinib (RINVOQ®) for treating adult patients with Giant Cell Arteritis (GCA). The recommendation is based on the Phase 3 SELECT-GCA trial results, which demonstrated efficacy in achieving sustained remission and other key endpoints.
If approved by the European Commission in the first half of 2025, RINVOQ would become the first and only oral advanced therapy for adults with GCA. The trial evaluated upadacitinib (15 mg, once daily) in adults aged 50 and older, comparing 7.5 mg or 15 mg doses combined with a 26-week corticosteroid taper regimen against placebo with a 52-week taper.
The safety profile during the 52-week, placebo-controlled period aligned with observations from other approved indications. RINVOQ is currently approved in the EU for multiple conditions including radiographic axial spondylarthritis, psoriatic arthritis, and Crohn's disease, though not yet for GCA.
AbbVie (NYSE: ABBV) has announced its upcoming participation in TD Cowen's 45th Annual Health Care Conference. The event will take place on Wednesday, March 5, 2025, featuring a management fireside chat scheduled for 8:10 a.m. Central time.
Investors and interested parties can access a live audio webcast of the presentation through AbbVie's Investor Relations website at investors.abbvie.com. An archived version of the session will be made available for viewing later the same day.
AbbVie (NYSE: ABBV) announced that CEO Robert A. Michael will assume the additional position of chairman, effective July 1, 2025, following the retirement of current chairman Richard A. Gonzalez. The board of directors unanimously elected Michael to the position, with lead independent director Roxanne S. Austin expressing complete confidence in his leadership.
Gonzalez, who has served as chairman since AbbVie's formation in 2013 and was formerly the company's CEO, will retire from the board. Additionally, Glenn F. Tilton, who served as lead independent director from 2013 to 2024, will also retire from AbbVie's board effective July 1, 2025.
AbbVie (NYSE: ABBV) has announced a quarterly cash dividend of $1.64 per share, payable on May 15, 2025, to stockholders of record as of April 15, 2025. The company has demonstrated strong dividend growth, increasing its dividend by 310 percent since its establishment in 2013. AbbVie maintains its position in the prestigious S&P Dividend Aristocrats Index, which recognizes companies with at least 25 consecutive years of dividend increases.